- Home
- CRDL vs VGI Comparison
CRDL vs VGI Comparison
Compare CRDL & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- VGI
- Stock Information
- Founded
- CRDL 2017
- VGI 2012
- Country
- CRDL Canada
- VGI United States
- Employees
- CRDL N/A
- VGI N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- VGI Investment Managers
- Sector
- CRDL Health Care
- VGI Finance
- Exchange
- CRDL Nasdaq
- VGI Nasdaq
- Market Cap
- CRDL 90.4M
- VGI 89.7M
- IPO Year
- CRDL N/A
- VGI N/A
- Fundamental
- Price
- CRDL $1.07
- VGI $7.97
- Analyst Decision
- CRDL Strong Buy
- VGI
- Analyst Count
- CRDL 2
- VGI 0
- Target Price
- CRDL $9.00
- VGI N/A
- AVG Volume (30 Days)
- CRDL 781.9K
- VGI 46.0K
- Earning Date
- CRDL 11-13-2025
- VGI 01-01-0001
- Dividend Yield
- CRDL N/A
- VGI 12.66%
- EPS Growth
- CRDL N/A
- VGI N/A
- EPS
- CRDL N/A
- VGI N/A
- Revenue
- CRDL N/A
- VGI N/A
- Revenue This Year
- CRDL N/A
- VGI N/A
- Revenue Next Year
- CRDL N/A
- VGI N/A
- P/E Ratio
- CRDL N/A
- VGI N/A
- Revenue Growth
- CRDL N/A
- VGI N/A
- 52 Week Low
- CRDL $0.77
- VGI $6.68
- 52 Week High
- CRDL $2.24
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- CRDL 44.27
- VGI 48.30
- Support Level
- CRDL $1.04
- VGI $7.92
- Resistance Level
- CRDL $1.16
- VGI $8.03
- Average True Range (ATR)
- CRDL 0.06
- VGI 0.06
- MACD
- CRDL 0.00
- VGI -0.00
- Stochastic Oscillator
- CRDL 18.00
- VGI 33.31
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.